Condition (MeSH)
Endolymphatic Hydrops
ClinicalTrials.gov lists 80 trials for Endolymphatic Hydrops or a narrower condition beneath it. Otonomy, Inc. has the most among industry and government lead sponsors, with 9.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
10 of the 80 trials are tagged with Endolymphatic Hydrops itself; the rest are tagged with a narrower condition beneath it.
When did Endolymphatic Hydrops trials start? (22)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 10
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 4 |
| 2024 | 3 |
| 2023 | 6 |
| 2022 | 6 |
| 2021 | 10 |
| 2020 | 5 |
| 2019 | 7 |
| 2018 | 5 |
| 2017 | 1 |
| 2016 | 7 |
Showing 10 of 22 earlier years.
No forecast is made for this condition: it averages 3.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 33 months from start to primary completion across 8 trials still running at the 2026-10-09 snapshot; registered median of 21 months across 51 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Endolymphatic Hydrops trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 1/2 | 4 |
| Phase 2 | 9 |
| Phase 2/3 | 3 |
| Phase 3 | 10 |
| Phase 4 | 9 |
| Not applicable | 26 |
| Observational | 15 |
How many Endolymphatic Hydrops trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 8 |
| Active, not recruiting | 3 |
| Completed | 39 |
| Terminated | 11 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Endolymphatic Hydrops trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Otonomy, Inc. | 9 |
| Sound Pharmaceuticals, Incorporated | 4 |
| Otolith Labs | 3 |
| Abbott | 1 |
| Alvogen Korea | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Endolymphatic Hydrops? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Betahistine | 5 |
| Ebselen | 4 |
| Gadopentetate Dimeglumine | 2 |
| METHYLPREDNISOLONE | 2 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Dexamethasone/Dexamethasone acetate | 10 |
| Drug | 1 |
| Anakinra alone (stages 2b/3) | 1 |
| Lamotrigine and Bupropion | 1 |
| Hyaluronic acid 1% | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Endolymphatic Hydrops trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Unsuccessful Initial Activation | 2 | 1 |
| Abdominal Pain and Constipation | 1 | 1 |
| Acute Myeloid Leukemia | 1 | 1 |
| Acute kidney injury | 1 | 1 |
| Anemia | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Endolymphatic Hydrops? (15)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
Showing 5 of 15 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.